Literature DB >> 22173052

Proteinase-activated receptor-2 is required for normal osteoblast and osteoclast differentiation during skeletal growth and repair.

S R Georgy1, C N Pagel, A Ghasem-Zadeh, R M D Zebaze, R N Pike, N A Sims, E J Mackie.   

Abstract

Proteinase-activated receptor-2 (PAR(2)) is a G-protein coupled receptor expressed by osteoblasts and monocytes. PAR(2) is activated by a number of proteinases including coagulation factors and proteinases released by inflammatory cells. The aim of the current study was to investigate the role of PAR(2) in skeletal growth and repair using wild type (WT) and PAR(2) knockout (KO) mice. Micro computed tomography and histomorphometry were used to examine the structure of tibias isolated from uninjured mice at 50 and 90 days of age, and from 98-day-old mice in a bone repair model in which a hole had been drilled through the tibias. Bone marrow was cultured and investigated for the presence of osteoblast precursors (alkaline phosphatase-positive fibroblastic colonies), and osteoclasts were counted in cultures treated with M-CSF and RANKL. Polymerase chain reaction (PCR) was used to determine which proteinases that activate PAR(2) are expressed in bone marrow. Regulation of PAR(2) expression in primary calvarial osteoblasts from WT mice was investigated by quantitative PCR. Cortical and trabecular bone volumes were significantly greater in the tibias of PAR(2) KO mice than in those of WT mice at 50 days of age. In trabecular bone, osteoclast surface, osteoblast surface and osteoid volume were significantly lower in KO than in WT mice. Bone marrow cultures from KO mice showed significantly fewer alkaline phosphatase-positive colony-forming units and osteoclasts compared to cultures from WT mice. Significantly less new bone and significantly fewer osteoclasts were observed in the drill sites of PAR(2) KO mice compared to WT mice 7 days post-surgery. A number of activators of PAR(2), including matriptase and kallikrein 4, were found to be expressed by normal bone marrow. Parathyroid hormone, 1,25 dihydroxyvitamin D(3), or interleukin-6 in combination with its soluble receptor down-regulated PAR(2) mRNA expression, and fibroblast growth factor-2 or thrombin stimulated PAR(2) expression. These results suggest that PAR(2) activation contributes to determination of cells of both osteoblast and osteoclast lineages within bone marrow, and thereby participates in the regulation of skeletal growth and bone repair. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22173052     DOI: 10.1016/j.bone.2011.11.023

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  11 in total

1.  Genetics of pleiotropic effects of dexamethasone.

Authors:  Laura B Ramsey; Stan Pounds; Cheng Cheng; Xueyuan Cao; Wenjian Yang; Colton Smith; Seth E Karol; Chengcheng Liu; John C Panetta; Hiroto Inaba; Jeffrey E Rubnitz; Monika L Metzger; Raul C Ribeiro; John T Sandlund; Sima Jeha; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Pharmacogenet Genomics       Date:  2017-08       Impact factor: 2.089

2.  Pharmacological Targeting of Protease-Activated Receptor 2 Affords Protection from Bleomycin-Induced Pulmonary Fibrosis.

Authors:  Cong Lin; Jan von der Thüsen; Joost Daalhuisen; Marieke ten Brink; Bruno Crestani; Tom van der Poll; Keren Borensztajn; C Arnold Spek
Journal:  Mol Med       Date:  2015-06-29       Impact factor: 6.354

3.  Evaluation of antibodies directed against human protease-activated receptor-2.

Authors:  Mark N Adams; Charles N Pagel; Eleanor J Mackie; John D Hooper
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-31       Impact factor: 3.000

4.  Membrane-anchored Serine Protease Matriptase Is a Trigger of Pulmonary Fibrogenesis.

Authors:  Olivier Bardou; Awen Menou; Charlène François; Jan Willem Duitman; Jan H von der Thüsen; Raphaël Borie; Katiuchia Uzzun Sales; Kathrin Mutze; Yves Castier; Edouard Sage; Ligong Liu; Thomas H Bugge; David P Fairlie; Mélanie Königshoff; Bruno Crestani; Keren S Borensztajn
Journal:  Am J Respir Crit Care Med       Date:  2016-04-15       Impact factor: 21.405

Review 5.  Serine proteinases in the turnover of the cartilage extracellular matrix in the joint: implications for therapeutics.

Authors:  David J Wilkinson; Maria Del Carmen Arques; Carmen Huesa; Andrew D Rowan
Journal:  Br J Pharmacol       Date:  2018-03-30       Impact factor: 8.739

6.  Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.

Authors:  Shoichiro Mukai; Kenji Yorita; Yukari Kawagoe; Yuichi Katayama; Kozue Nakahara; Toyoharu Kamibeppu; Satoru Sugie; Hiromasa Tukino; Toshiyuki Kamoto; Hiroaki Kataoka
Journal:  Hum Cell       Date:  2014-09-04       Impact factor: 4.174

Review 7.  Rheumatic Disease: Protease-Activated Receptor-2 in Synovial Joint Pathobiology.

Authors:  Kendal McCulloch; Sarah McGrath; Carmen Huesa; Lynette Dunning; Gary Litherland; Anne Crilly; Leif Hultin; William R Ferrell; John C Lockhart; Carl S Goodyear
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-23       Impact factor: 5.555

8.  Stem cell library screen identified ruxolitinib as regulator of osteoblastic differentiation of human skeletal stem cells.

Authors:  Nihal AlMuraikhi; Dalia Ali; Aliah Alshanwani; Radhakrishnan Vishnubalaji; Muthurangan Manikandan; Muhammad Atteya; Abdulaziz Siyal; Musaad Alfayez; Abdullah Aldahmash; Moustapha Kassem; Nehad M Alajez
Journal:  Stem Cell Res Ther       Date:  2018-11-21       Impact factor: 6.832

9.  PAR2 Deficiency Induces Mitochondrial ROS Generation and Dysfunctions, Leading to the Inhibition of Adipocyte Differentiation.

Authors:  Yeo Jin Park; Bonggi Lee; Dae Hyun Kim; Eun-Bin Kwon; Younghoon Go; Sugyeong Ha; Min-Kyeong Lee; Hak Sun Yu; Hae Young Chung
Journal:  Oxid Med Cell Longev       Date:  2021-06-08       Impact factor: 6.543

Review 10.  Bone Metastasis from Renal Cell Carcinoma.

Authors:  Szu-Chia Chen; Po-Lin Kuo
Journal:  Int J Mol Sci       Date:  2016-06-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.